Medicare (and Medicare Advantage) provide some coverage for dementia, beginning with the diagnosis, says Baumgart.
The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild ...
Alzheimer’s has no cure and can’t be reversed, but the FDA-approved drug can slow cognitive decline. Eli Lilly reported that ...
FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ – – Second designation received for Lomecel-B™ for the treatment of mild Alzheimer’s Disease after ...
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates ...
It's not a cure-- but it is a step in the right direction.This month-- a new medication for alzheimer's, called 'kinsul'a, ...
Novo Holdings led Asceneuron’s $100 million Series C financing. The Merck Serono spinout’s lead program is an oral small molecule designed to prevent aggregation of tau protein in neurodegenerative ...
Positrigo, a Swiss based company developing nuclear medical imaging devices to advance functional brain imaging, has achieved ...
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage ...
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial ...